Sno, you are getting hysterical again. I can only imagine how your posts will degrade(is that possible) as happy hour approaches on a friday.
I am not an apologist for JJ. I just think it serves no useful purpose, at this point, to be rude and demand resignation. Its way too late in the game for that. He has all the motivation in the world to do the right thing here, but maybe not the skill set. I dont know. The past has certainly been one misstep after the other.
I wish he would release more data, but the koreans may have not provided. There just isnt enough public info for shareholders really know whats going on.
What we do know is that the Koreans hold the keys to the kingdom. And. they have a fairly large stake in the success of rgrx too. Gtree has held up well, and being more liquid, is a better proxy for what is going on here than the action in rgrx. A 100k$ can take rgrx down 20%. Thats nuts but it is what it is.
JJ needs to be more proactive put all info out there. If he knows the intent of gtree(selling the JV) he should say "we are in negotiations to sell JV, there is no guarantee that sale will take place..etc". That is done all the time.
No argument................JJ Needs to Step Up.
Man reseller, you are so dam clueless. If the advisors talk Ma into doing a RS to get more attention and possible institutional ownership, it will be the end of vaso. The shorts would crush this stock after hearing a CC like today. This company is a joke and has only retail owners for a reason.
Compnay is best in the shadows. And the company knows this. They can just sit back and collect fat compensation and defend it by talking about meaningless rev increases.
Nothing but more lies. He blames stock price on being a pink sheet stock. Then he accuses caller who complained of lack of response when e mailing company that he was e mailing to the wrong address.
Also hinting to a RS.
These knuckleheads think they are running a private company.
No need to worry about my IQ sno. Its the same IQ that bought scln below a buck and rgrx below a dime when you were endlessly bashing both.
I do agree with you that rgrx would be a better buy than gtree, but thats not saying alot. Gtree is more than TB4. It bought a glioblastoma drug and it still has some tech. Gtree's model is to sell the JV and show the street that it can monitize quickly and then move on, maybe with another TB4 indication. This would be in the best interest of rgrx also.
No way can NVS pay a premium to the ALREADY $360 million market cap of G Tree shares
Why do you keep going back to a buyout of gtree and its unlikelyhood due to market cap? We are talking
about NVS getting all the rights to dry eye; thats it. They dont have to buy gtee, sno. Why cant you understand that simple concept?? They just need to buy the JV and acquire rights on EU from rgrx. In what world does that have anything to do with the market cap of gtree??
Thanks for sharing that pertinent, very timely information. Long timers here had no clue as to JJ's speaking aptitude. That certainly makes trial results and possible NVS negotiations much less relevant.
Sno, you always speak with such certainty, but you and the rest of us shareholders have no clue what is going on. So, chill on the hysterical nonsense. But, one thing for sure, something is going on, or Gtree and rgrx would not be trading as well as they are.
I speculate that NVS is circling. The Koreans have no intention of taking this drug to fda approval. Do the Koreans make them pay a fair price.? It all depends on how they choose to interprete the data. If they believe in headline of rodman,,,,,,"approvable endpoints identified and Met", bid will be coming soon imho
Lots on unanswered questions in regard to JJ. We have been told for years about the partnership potential; in heart, in eyes, in neuro, in skin-cosmetic and wounds. And the years go by and nothing. Granted, we got a lifesaver from the koreans, but why not AGN or Novartis or other Big bio, they clearly had huge interest in Dry eye last year. Was it that JJ wanted too much for any deal, or was the interest really not that strong.? We will never know.
I maintain that JJ is aligned with us. But, there is no time to waste. Someone said here stock was sliding down after good news. News flash; company missed 2 endpoints. That is a bad result by any measure and stock holding well considering. That tells you that Donks theory may be in play or other results coming or Novartis is content with details of trial and Koreans will sell soon. Only Insiders know. In the meantime,
JJ needs to defend stock. There is only one way.....more information......eye pressure and need for CAE? or OSDI.
and he has been an anathema to outsider shareholders for over a decade.
And please tell us why he would not want to maximize shareholder value when most of his net worth is comprised of that 1.4% stake. That doesnt include some of his recent options.
And the veto is a rgrx veto, not a personel veto.
Geezer you are becoming the new 1/2 empty kind of guy. Its a little late in the game for that. Take a good bm and chill. Lots in the works here and more data coming shortly.
Sno. come on? What does the market cap of Gtree have to do with Novartis acquiring the rights for dry eye. Those rights are owned by the JV. Gtree wants to sell and Novartis(hopefully) wants to buy ReGenTree(jV). Now, if Novartis wants the whole ball of wax, they can buy the EU rights from rgrx also. But, market cap of Gtree is only important in that it shows how much more value the Korean market is giving to TB4.
Calm down sno. Do yourself a favor and take the rest of the night off. You dont have to like jj to know that rgrx's fate is really not in his hands anymore. He has had enough swings at the plate. He will have to accept the monetization of dry eye; sale of JV or EU rights or both. The Koreans are not going to take this to a 2018 NDA, regardless of what that press release said.
Dimwit bros have sustained too many hits to the head. The last 2 days they rec dis and nok. Dont worry, just pay for postage and handling, the book is free......................................
How are these guys allowed on a business channel and who would EVER give them money to manage. Oh the humanity!............
Now that the koreans have spent money to find easily approvable endpoint, I think Lee's will start trial there very soon. China market has been totally forgotten.
And JJ should be talking to Big pharma about partnering/selling EU rights. Novartis is likely buyer, but might motivated them further in terms of timing and price if they know others are interested. Lets just not let this be totally Korean driven.
Rodman report is nice and has some good points(all of which have been discussed here before the report even came out) but he totally ignores the Gtree effect and Lees. And NK?!
Great report, all should read. Yahoo will not let me post. Report is written "after discussions with management."
Believes CAE is not required for approval. Report goes into Lifitegrast comparision; as noted by sno did not use CAE in their main trial. Appoval there is very good for approval for TB4